D-dimer levels and recurrence in patients with unprovoked VTE and a negative qualitative D-dimer test after treatment

Thromb Res. 2016 Oct:146:119-125. doi: 10.1016/j.thromres.2016.06.023. Epub 2016 Jun 23.

Abstract

Background: The rate of recurrent venous thromboembolism (VTE) in patients with a first unprovoked VTE who had a negative qualitative D-dimer test one month after stopping anticoagulant therapy was higher than expected in the D-dimer Optimal Duration Study (DODS).

Objectives: To determine whether quantitative D-dimer levels using a low threshold, age- and sex-specific thresholds, or repeated measurements, would improve identification of patients at low risk of recurrent VTE.

Materials and methods: D-dimer levels were quantified in banked samples from 307 patients in DODS who had a negative qualitative D-dimer test while on, and 1month after stopping, anticoagulant therapy and the rates of recurrent VTE were determined in patients with D-dimer levels below various predefined thresholds.

Results: The rate (per patient year) of recurrent VTE was: 5.9% with D-dimer levels<250μg/l at one month; 5.2% with D-dimer levels between 250 and 499μg/l at one month; 5.0% with D-dimer levels less than predefined age- and sex-specific thresholds at one month; and 6.3% when D-dimer levels were <500μg/l at both one and 7months after stopping anticoagulant therapy. These rates are similar to the overall event rate of 6.3% in patients who stopped treatment.

Conclusions: Among unprovoked VTE patients who had a negative qualitative D-dimer test during and after anticoagulant therapy, low D-dimer thresholds, age and sex-adjusted thresholds or repeated measurements, did not identify subgroups with a very low rate of recurrence.

Keywords: Cohort study; D-dimer; Forecasting; Prognosis; Venous thrombosis.

MeSH terms

  • Anticoagulants / therapeutic use*
  • Cohort Studies
  • Female
  • Fibrin Fibrinogen Degradation Products / metabolism*
  • Humans
  • Male
  • Prognosis
  • Recurrence
  • Risk Assessment
  • Risk Factors
  • Venous Thromboembolism / drug therapy*

Substances

  • Anticoagulants
  • Fibrin Fibrinogen Degradation Products
  • fibrin fragment D